Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey

Objective: Dyslipidaemia is among the most important risk factors for coronary heart disease (CHD). The lowering of LDL-cholesterol (LDL-C) yields significant reduction in both morbidity and mortality rates, particularly in patients with established CHD. The aim of this survey was to assess how dyslipidaemia is managed following a coronary event in different places in Europe. Methods: CHD patients' data from centres in 22 European countries were gathered using standardised methods. In total, 8467 CHD patients with lipid measurements in one central laboratory were included. Trends from 8 countries participating in all three EUROASPIRE surveys (1994e1995, 1999-2000, 2006-2007) were also investigated. Results: 51.1% of CHD patients had elevated total cholesterol (-4.5 mmol/L), 54.5% had raised LDL-C (-2.5 mmol/L), 36.7% had low HDL-C (< 1.0 mmol/L for men and < 1.2 mmol/L for women), and 34.7% had increased triglycerides (-1.7 mmol/L). The use of lipid lowering drugs was 79.8% but it varied considerably, ranging from only 41.6% (Lithuania) to 95.4% (Finland). Over the past decade, in 8 countries the prevalence of hypercholesterolaemia (-4.5 mmol/L) in CHD patients has decreased from 94.5% in the first to 76.7% in the second and 46.2% in the third survey (p < 0.0001). The use of lipid-lowering drugs increased from 32.3% in the first, to 62.7% in the second and 88.8% in the third survey (p < 0.0001). Conclusions: Although management of dyslipidaemia in CHD patients is improving, a large majority of CHD patients with dyslipidaemia is still inadequately treated and many patients on lipid-lowering therapy are not reaching the treatment goals. Therefore, a considerable potential still exists throughout Europe to reduce CHD mortality and morbidity rates through better treatment of dyslipidaemia. -2013 Elsevier Ireland Ltd. All rights reserved.